Results
61
Strong Balance Sheet Stocks: companies with a Health score of at least 4, ordered by Health score.
61 companies
Clinuvel Pharmaceuticals
Market Cap: AU$546.1m
A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
CUV
AU$10.92
7D
3.4%
1Y
-27.9%
Little Green Pharma
Market Cap: AU$31.9m
Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.
LGP
AU$0.10
7D
0%
1Y
-16.0%
OncoSil Medical
Market Cap: AU$13.8m
A medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in Australia, New Zealand, and Europe.
OSL
AU$0.003
7D
-14.3%
1Y
-40.0%
Alterity Therapeutics
Market Cap: AU$100.4m
Engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia.
ATH
AU$0.011
7D
0%
1Y
120.0%
Firebrick Pharma
Market Cap: AU$14.8m
Engages in the development and commercializing of novel formulations for the uses of povidone iodine in Australia.
FRE
AU$0.066
7D
-7.0%
1Y
17.9%
Vita Life Sciences
Market Cap: AU$100.4m
A healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China.
VLS
AU$1.82
7D
1.1%
1Y
-19.5%
Immutep
Market Cap: AU$416.2m
A late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia.
IMM
AU$0.28
7D
-3.4%
1Y
-35.2%
Invion
Market Cap: AU$10.1m
A clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia.
IVX
AU$0.11
7D
32.5%
1Y
-72.5%
Proteomics International Laboratories
Market Cap: AU$55.0m
Operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and South East Asia.
PIQ
AU$0.42
7D
2.4%
1Y
-57.6%
LTR Pharma
Market Cap: AU$58.8m
A biopharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia.
LTP
AU$0.33
7D
-4.4%
1Y
-45.4%
Argenica Therapeutics
Market Cap: AU$105.0m
A biotechnology company, engages in the research and development of neuroprotective therapeutic drug in Australia.
AGN
AU$0.82
7D
-0.6%
1Y
6.5%
Radiopharm Theranostics
Market Cap: AU$53.7m
Engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs.
RAD
AU$0.023
7D
9.5%
1Y
-30.3%
Neuren Pharmaceuticals
Market Cap: AU$1.8b
A biopharmaceutical company, develops drugs for the treatment of neurological disorders.
NEU
AU$14.13
7D
10.0%
1Y
-31.8%
Nyrada
Market Cap: AU$32.7m
A pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases.
NYR
AU$0.15
7D
10.7%
1Y
167.2%
Arovella Therapeutics
Market Cap: AU$88.8m
A biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally.
ALA
AU$0.075
7D
4.2%
1Y
-31.8%
Algorae Pharmaceuticals
Market Cap: AU$10.1m
A pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand.
1AI
AU$0.006
7D
0%
1Y
-50.0%
Hexima
Market Cap: AU$2.2m
Does not have significant operations.
HXL
AU$0.013
7D
0%
1Y
-18.8%
Cleo Diagnostics
Market Cap: AU$46.3m
A medical diagnostics and devices company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia.
COV
AU$0.36
7D
2.9%
1Y
56.5%
Invex Therapeutics
Market Cap: AU$7.0m
A biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia.
IXC
AU$0.093
7D
-1.1%
1Y
22.4%
Clarity Pharmaceuticals
Market Cap: AU$694.1m
A clinical stage radiopharmaceutical company, engages in research and development and clinical stage radiopharmaceuticals products in Australia and the United States.
CU6
AU$2.16
7D
-5.7%
1Y
-53.7%
Actinogen Medical
Market Cap: AU$65.8m
A biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia.
ACW
AU$0.021
7D
0%
1Y
-27.6%
Biotron
Market Cap: AU$4.0m
A biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia.
BIT
AU$0.003
7D
20.0%
1Y
-94.6%
Botanix Pharmaceuticals
Market Cap: AU$735.3m
Engages in the research and development of dermatology and antimicrobial products in Australia and the United States.
BOT
AU$0.38
7D
0%
1Y
33.9%
Race Oncology
Market Cap: AU$231.9m
A clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments.
RAC
AU$1.34
7D
-4.0%
1Y
-7.0%
Percheron Therapeutics
Market Cap: AU$10.9m
Engages in the research and development of novel antisense pharmaceuticals in Australia.
PER
AU$0.01
7D
0%
1Y
-86.5%
EZZ Life Science Holdings
Market Cap: AU$72.4m
Engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and internationally.
EZZ
AU$1.54
7D
-1.6%
1Y
56.6%
Genetic Signatures
Market Cap: AU$109.0m
Operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas.
GSS
AU$0.48
7D
-16.5%
1Y
-34.2%
Amplia Therapeutics
Market Cap: AU$19.8m
A clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia.
ATX
AU$0.051
7D
0%
1Y
-23.9%
PYC Therapeutics
Market Cap: AU$699.9m
A drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.
PYC
AU$1.20
7D
0%
1Y
20.0%
Orthocell
Market Cap: AU$296.4m
A regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia, the United States, the United Kingdom, and the European Union.
OCC
AU$1.23
7D
-0.4%
1Y
226.7%
Emyria
Market Cap: AU$11.8m
Engages in delivering and developing of new treatments for unmet needs in mental health and select neurological conditions in Australia.
EMD
AU$0.024
7D
-20.0%
1Y
-59.3%
Island Pharmaceuticals
Market Cap: AU$46.3m
A drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections in Australia and the United States of America.
ILA
AU$0.22
7D
-4.3%
1Y
189.5%
Immuron
Market Cap: AU$16.8m
A biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada.
IMC
AU$0.072
7D
12.5%
1Y
-25.8%
NeuroScientific Biopharmaceuticals
Market Cap: AU$8.4m
Engages in the research and development of novel peptide-based pharmaceutical products.
NSB
AU$0.058
7D
9.4%
1Y
16.0%
Tissue Repair
Market Cap: AU$11.2m
A clinical stage biopharmaceutical company, develops advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia.
TRP
AU$0.18
7D
-5.1%
1Y
-21.3%
Vitrafy Life Sciences
Market Cap: AU$96.1m
Provides cryopreservation solutions in Australia.
VFY
AU$1.51
7D
0.7%
1Y
n/a